Choosing new therapies for gonorrhoea: we need to consider the impact on the pan-Neisseria genome: a viewpoint

Research output: Contribution to journalA1: Web of Science-article

Abstract

The development of new gonorrhoea treatment guidelines typically considers the resistance-inducing effect of the treatment only on Neisseria gonorrhoeae. Antimicrobial resistance in N. gonorrhoeae has, however, frequently first emerged in commensal Neisseria species and then been passed on to N. gonorrhoeae via transformation. This creates the rationale for considering the effect of gonococcal therapies on resistance in commensal Neisseria. We illustrate the benefits of this pan-Neisseria strategy by evaluating three contemporary treatment options for N. gonorrhoeae-ceftriaxone plus azithromycin, monotherapy with ceftriaxone and zoliflodacin.

Original languageEnglish
Article number515
JournalAntibiotics-Basel
Volume10
Issue number5
Number of pages12
ISSN2079-6382
DOIs
Publication statusPublished - 2021

Keywords

  • N
  • gonorrrhoeae
  • Neisseria
  • antimicrobial resistance
  • antimicrobial consumption
  • dual therapy
  • ANTIMICROBIAL RESISTANCE
  • EUROPEAN GUIDELINE
  • EPIDEMIOLOGY
  • AZITHROMYCIN
  • MACROLIDE

Cite this